Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

LZM-005

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Livzon Pharma

Drug class:

HER2 inhibitor

Related drugs:

‹

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

trastuzumab (407)

lapatinib (107)

neratinib (102)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

mobocertinib (12)

trastuzumab-dttb (11)

zanidatamab-hrii (10)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab-IFN-β mutein (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

BAY 2927088 (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

HLX11 (pertuzumab biosimilar) (0)

Hervycta (trastuzumab biosimilar) (0)

JNJ-26483327 (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
KMT2B mutation	HER2 Positive Breast Cancer	KMT2B mutation	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
KIR3DL2 mutation	HER2 Positive Breast Cancer	KIR3DL2 mutation	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3	trastuzumab + LZM-005 Sensitive: C3 – Early Trials trastuzumab + LZM-005 Sensitive : C3
KIR3DL2 mutation	HER2 Positive Breast Cancer	KIR3DL2 mutation	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3
MUC16 mutation	HER2 Positive Breast Cancer	MUC16 mutation	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3
KMT2B mutation	HER2 Positive Breast Cancer	KMT2B mutation	HER2 Positive Breast Cancer	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3	LZM-005 Sensitive: C3 – Early Trials LZM-005 Sensitive : C3